rs104894362
Variant summary
Our verdict is Pathogenic. The variant received 19 ACMG points: 19P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_004985.5(KRAS):c.468C>G(p.Phe156Leu) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. F156I) has been classified as Pathogenic.
Frequency
Consequence
NM_004985.5 missense
Scores
Clinical Significance
Conservation
Publications
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 19 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Cardiofaciocutaneous syndrome 2 Pathogenic:1
- -
KRAS-related disorder Pathogenic:1
The KRAS c.468C>G variant is predicted to result in the amino acid substitution p.Phe156Leu. This variant has been reported in patients diagnosed with Costello syndrome (Patient 12 in Zenker et al. 2007. PubMed ID: 17056636), Noonan syndrome (Patient 24 in Table S4 in Bessis et al. 2019. PubMed ID: 30417923; Supplementary Table 1 in Li et al. 2019. PubMed ID: 31219622) and as de novo in a patient with cardio-facio-cutaneous (Søvik et al. 2009. PubMed ID: 21686750). Functional studies showed that this variant led to an increase in GDP/GTP exchange and a reduction in GAP-stimulated GTPase rates (Gremer et al. 2011. PubMed ID: 20949621; Schubbert et al. 2007. PubMed ID: 17875937 ). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. In addition another variant impacting the same amino acid residue (p.Phe156Ile) has been documented in a patient with a KRAS-related disorder (Patient 11 in Zenker et al. 2007. PubMed ID: 17056636). Based on this evidence, the c.468C>G (p.Phe156Leu) variant is interpreted as pathogenic. -
not provided Pathogenic:1
Heterozygous for the F156L mutation in the KRAS gene, consistent with the diagnosis of a disorder in the Noonan syndrome spectrum.p.Phe156Leu (TTC>TTG):c.468 C>G in exon 5 of the KRAS gene (NM_004985.3)The F156L missense mutation in the KRAS gene has been reported previously in a 14 month old male who was diagnosed with Costello syndrome with hypertrophic cardiomyopathy, ASD and pulmonic stenosis, developmental delay, and mild-moderate mental retardation, failure to thrive, severe feeding difficulties, loose and redundant skin with deep palmar and plantar creases, Dandy-Walker malformation, and facial dysmorphism (Zenker et al., 2007). Another missense mutation of the same codon, F156I, was described in a patient with features of both Noonan and CFC syndrome (Zenker et al., 2007). Additionally, functional in vitro studies have demonstrated that the F156L mutation results in profound activation of the MAPK pathway (Gremer et al, 2011). The variant is found in NOONAN panel(s). -
RASopathy Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at